First in Human Study for the Assessment of Safety and Initial Performance of the EAS1 System

A Prospective, open label, multi center, single arm, First in Human study to assess the safety and initial performance of EAS1 system for Irreversible Electroporation (IRE) ablation of lung cancer in subjects eligible for tumor resection

Trial Details

NCT ID
NCT06423690
Phase
NA
Sponsor
Snipe Medical
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • EAS1 System
Locations (sample)
  • Kfar Saba, Israel|32.175,34.90694
  • Salamanca, Spain|40.42972,-3.67975
  • London, United Kingdom|51.50853,-0.12574

Key Eligibility Criteria

  • Adult male and female subjects (age ≥18 years at the date of informed consent signature)
  • Subject is capable and willing to provide an informed consent
  • Subjects with a known diagnosis of lung cancer at cT1a-T1c, cN0 stages
  • At least one pulmonary tumor (primary or metastasis) ≤ 30 mm in maximal diameter, as confirmed by the latest standard of care imaging (CT/MRI), per…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →